Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Date of Graduation
Objective: Assess the ability of continuous pulmonary artery pressure monitoring via implantable CardioMEMs HF device to reduce hospitalization in New York Heart Association (NYHA) Class III heart failure patients over the age of 18. Design: Systematic literature review. Methods: Searches were conducted via PubMed and ClinicalTrials.gov using the single search term “CardioMEMs.” Inclusion criteria narrowed results to studies performed in the last 10 years, randomized control trials, cohort studies, and utilizing heart failure related hospitalization as the primary endpoint. Results: The current data unanimously asserts that the CardioMEMs HF device is effective at reducing heart failure related hospitalizations, with secondary evidence suggestive of the potential to improve NYHA classification. Conclusion: The findings of this literature review support the use of the CardioMEMs HF device in lieu of conventional management, although more data is needed before it can be universally recommended as the new standard of care.
Andrunik, Eady, et al. Use of CardioMEMs HF Sensor in Management of NYHA Class III Heart Failure. James Madison University. 2022.